Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Institute Catalá Oncología
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Institute Catalá Oncología (5)
2024
2023
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041
2022
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
-
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
BMC Cancer, Vol. 22, Núm. 1